Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Name Battles May Be Waged More Publicly; FDA Petitioned On Zentase

Executive Summary

FDA's efforts to pre-empt trade name conflicts by shifting decisions to earlier in the application process are still just getting off the ground. In one case, though, a company has taken matters into its own hands and is pressing the agency to make an early, public determination about whether a proposed brand name is acceptable

You may also be interested in...



Trade Name Review May Shift To Firms, But FDA Unclear Which Tests To Use

FDA is asking firms to use computerized methods and algorithms that can detect product name similarities as part of a pilot designed to expedite name review. The program, under which companies would generate their own data and submit it to FDA for review, will be discussed at a June 5-6 public meeting

Trade Name Review May Shift To Firms, But FDA Unclear Which Tests To Use

FDA is asking firms to use computerized methods and algorithms that can detect product name similarities as part of a pilot designed to expedite name review. The program, under which companies would generate their own data and submit it to FDA for review, will be discussed at a June 5-6 public meeting

FDA’s 5-Year Plan For User Fees Puts Post- And Pre-Market On Equal Footing

Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market

Related Content

UsernamePublicRestriction

Register

PS049475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel